Grobet-Jeandin Élisabeth, Pinar Ugo, Loriot Yohann, Roupret Morgan
Département d'urologie, Hôpitaux universitaires de Genève, Genève, Suisse - Sorbonne Université, GRC n° 5, PREDICTIVE ONCO-UROLOGY, AP-HP, groupe hospitalier La Pitié-Salpêtrière, service d'urologie, Paris, France.
Sorbonne Université, GRC n° 5, PREDICTIVE ONCO-UROLOGY, AP-HP, groupe hospitalier La Pitié-Salpêtrière, service d'urologie, Paris, France.
Rev Prat. 2021 Apr;71(4):391-395.
"Treatment of bladder cancer with immune checkpoints inhibitors .Checkpoint inhibitors could lead to a significant improvement in the management of bladder cancer. For metastatic bladder cancer, checkpoint inhibitors showed an improved overall survival and are currently recommended in second intention. Moreover, they could be used in replacement of standard chemotherapy in the case of muscle- invasive tumors. Finally, they appear to decrease the risk of recurrence after initial BCG treatment failure in the case of non-muscle-invasive tumors. For these three diseases forms, numerous ongoing trials are striving to demonstrate checkpoint inhibitors value."
用免疫检查点抑制剂治疗膀胱癌。检查点抑制剂可显著改善膀胱癌的治疗。对于转移性膀胱癌，检查点抑制剂显示出总体生存率的提高，目前被推荐为二线治疗。此外，对于肌肉浸润性肿瘤，它们可用于替代标准化疗。最后，对于非肌肉浸润性肿瘤，在初始卡介苗治疗失败后，它们似乎可降低复发风险。针对这三种疾病形式，众多正在进行的试验正在努力证明检查点抑制剂的价值。
